Strength of Objective Indicia from Prior Litigation Overcomes Strong Obviousness Challenge in IPR

Aug 19, 2020

Reading Time : 3 min

In RTI Surgical, Inc. v. LifeNet Health, the petitioner challenged various claims of a patent directed to a soft tissue graft product. Although the Patent Trial and Appeal Board agreed with the petitioner that nearly all of the claims were anticipated, the patent owner managed to save one dependent claim—claim 4—that differed from the other claims in that it required the soft tissue graft to be suitable for use “without rehydration.”

Because of this additional limitation, petitioner argued that claim 4 would have been obvious in light of the anticipating references and an additional piece of prior art that taught a way to use soft tissue grafts without rehydration. The board reviewed this prior art and determined that all of the elements of claim 4 could be found in those references. The board further found that petitioner made a “moderately persuasive” showing that a skilled artisan would have been motivated to make the proposed combination of references with a reasonable expectation of success. The patent owner, however, marshalled enough objective indicia of nonobviousness—including (i) whether there existed a long-felt but unresolved need, (ii) the failure of others, (iii) industry adoption of the patented invention, (iv) industry praise and (v) commercial success of the patented invention—to overcome the petitioner’s obviousness showing.

Much of the most persuasive objective indicia evidence came from an earlier successful lawsuit. The patent owner had previously sued a company called LifeCell for infringing a patent related to the patent under review, and successfully obtained a $35 million judgment. In the IPR, the patent owner used trial transcripts and documents containing sales information from this lawsuit as objective evidence that claim 4 was not obvious. 

To make the objective indicia evidence relevant, the patent owner had to first establish a “nexus” between the merits of claim 4 and LifeCell’s product sales. This required a fairly extensive showing by the patent owner. First, it submitted an expert declaration comparing claim 4 to LifeCell’s soft tissue graft products, concluding that the product was covered by—and co-extensive with—the claims. Then, the patent owner provided evidence that LifeCell advertisements specifically touted that its soft tissue grafts were “ready to use” because they did not require rehydration. Petitioner attempted to counter patent owner’s “nexus” showing by arguing that the benefits of the LifeCell soft tissue graft product stemmed from their unpatented features. The board dismissed this counterargument because petitioner did not provide evidence to support it. 

With nexus established, the patent owner provided evidence of two types of objective indicia that the board found very persuasive: industry adoption and commercial success. Specifically, the patent owner submitted undisputed evidence that LifeCell, an industry-leading manufacturer, had shifted its product sales from a noninfringing soft tissue graft product to an infringing soft tissue graft product and upon doing so, the infringing product cannibalized sales of the noninfringing product. The patent owner further submitted undisputed evidence that the infringing soft tissue graft product accounted for a significant part of LifeCell’s revenues. The board found that this evidence demonstrated that the market preferred and rapidly adopted the invention of claim 4, making it less likely that the invention was obvious.

The patent owner had presented additional objective indicia evidence that the board did not find persuasive. Specifically, the patent owner provided evidence of a failure by LifeCell to develop a noninfringing ready-to-use graft product. But the board gave this evidence little weight because it involved a single entity attempting a single failed approach. The board further disregarded the patent owner’s evidence of industry praise as too insignificant. The alleged “praise” consisted only of two isolated instances, one of which the board characterized as anonymous and promotional in nature. Moreover, the board gave no weight to the patent owner’s evidence of “long-felt need” because the evidence post-dated the filing of the patent application. 

Taking all of the evidence together, the board ultimately determined that the patent owner’s “objective indicia” evidence of nonobviousness outweighed the petitioner’s obviousness evidence and concluded that claim 4 was not obvious. 

Practice Tip: When faced with a strong obviousness challenge, a patent owner should consider presenting evidence of objective indicia of nonobviousness. This may include evidence of record from a prior litigation. To successfully rely on that evidence, a patent owner must establish a nexus between the evidence presented and the claimed features.    

RTI Surgical, Inc. v. Lifenet Health, IPR2019-00572, Paper 74 (PTAB August 4, 2020).

Share This Insight

Previous Entries

IP Newsflash

October 1, 2025

In a recent final written decision, the PTAB determined that a reference patent was not prior art, despite the petitioner’s post‑filing attempt to correct its petition. While the petitioner argued that it intended to rely on the patent application’s earlier date of publication, both the corrected petition and the expert declaration continued to reference the issued patent rather than the published application.

...

Read More

IP Newsflash

September 30, 2025

The USPTO Director recently granted a petitioner’s request for rehearing of the decision discretionarily denying institution of inter partes review, ultimately vacating the original decision, and referring the petition to the board for an institution decision.

...

Read More

IP Newsflash

September 25, 2025

In considering claims to a method of reducing cardiovascular events, the Federal Circuit held that the term a “clinically proven effective” amount did not render the claims patentable over the prior art. Specifically, the Federal Circuit held that the “clinically proven effective” amount, whether limiting or not, could not be used to distinguish the prior art because the claims also specified the exact amount of the drugs to be administered in the method. The Federal Circuit also rejected patentee’s evidence of unexpected results because that evidence was tied solely to the “clinically proven effective” limitation.

...

Read More

IP Newsflash

September 24, 2025

The Federal Circuit reversed a district court’s denial of judgment as a matter of law on non-infringement, thereby setting aside a $106 million jury verdict, after holding that prosecution history estoppel barred the patentee from asserting infringement under the doctrine of equivalents.

...

Read More

IP Newsflash

September 17, 2025

A magistrate judge in the District of Delaware issued a Report and Recommendation, that found the sole asserted claim was a “single means” claim and therefore invalid for lack of enablement. In reaching that conclusion, the magistrate judge rejected the patentee’s argument that the preamble of the claim disclosed a second element that satisfied the combination requirement of Section 112, paragraph 6 because the preamble simply recited a descriptor of the very apparatus that was the subject of the means-plus-function limitation in the body of the claim. The district court judge presiding over this case has scheduled a hearing to review the magistrate’s ruling.

...

Read More

IP Newsflash

September 9, 2025

The Federal Circuit has affirmed the PTAB’s determination that a patent challenger did not show the challenged claims were unpatentable for obviousness. The Federal Circuit concluded that substantial evidence, which included expert testimony, showed there was no motivation to combine the references.

...

Read More

IP Newsflash

August 29, 2025

In a recent order addressing four IPR proceedings, the PTAB exercised its inherent authority under 37 C.F.R. § 42.5(a) to sua sponte authorize post-hearing discovery on a potentially dispositive privity issue. The order followed a Director review decision that vacated and remanded earlier IPRs involving the same parties, patent family, and privity issue. 

...

Read More

IP Newsflash

August 29, 2025

The Patent Trial and Appeal Board denied institution of an inter partes review petition in part because it determined that a patent reference was not prior art under the common ownership exception of pre-AIA 35 U.S.C. § 103(c)(1).

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.